The Ludwig Institute for Cancer Research has appointed David Lane to be its new scientific director, effective June 1. He succeeds Andrew Simpson, who was scientific director for five years, from 2007 to 2012.
Lane is credited with the discovery of the p53 protein, an important tumor suppressor that is either mutated or faulty in about half all cancers. His current research efforts are focused on controlling p53 and identifying targets for new cancer therapies.
Currently, he is chief scientist at Singapore's Agency for Science, Technology, and Research, and he will retain that post in addition to his new role at Ludwig. Lane also formerly was a program director at Imperial College, ICRF Laboratories, and Clare Hall. He also helped establish the Cancer Research Campaign laboratories at the University of Dundee. He also served as Cancer Research UK's first chief scientist.
Illumina has elected Gerald Möller and David Walt to its board of directors for a three-year term until its annual meeting of stockholders in 2016. The firm has also elected Robert Epstein to its board for one year, until the annual meeting of stockholders in 2014.